Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology is designed to make immune cells more effective in killing tumor cells.
The following is an investor update, effective January 2023, presented by Robert Bitterman. Mr. Bitterman has been a member of the Board since 2012. He was appointed President and CEO in February of 2023.
Provided by Refinitiv.
Nov 8 - Nov 11, 2022SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 37TH ANNUAL MEETING
Jun 3 - Jun 7, 20222022 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 16 - May 19, 2022AMERICAN SOCIETY FOR GENE AND CELL THERAPY (ASGCT) 25TH ANNUAL MEETING